Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cyclophosphamide hydrate 是一种 DNA 烷化剂,一种 DNA 合成抑制剂。Cyclophosphamide hydrate 具有抗肿瘤活性、免疫抑制活性等。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 135 | 现货 | ||
10 mg | ¥ 182 | 现货 | ||
25 mg | ¥ 276 | 现货 | ||
50 mg | ¥ 386 | 现货 | ||
100 mg | ¥ 540 | 现货 | ||
200 mg | ¥ 763 | 现货 | ||
500 mg | ¥ 1,060 | 现货 | ||
1 g | ¥ 1,660 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 165 | 现货 |
产品描述 | Cyclophosphamide hydrate is a DNA alkylating agent, an inhibitor of DNA synthesis. Cyclophosphamide hydrate has antitumor and immunosuppressive activities. |
体外活性 |
方法:巨噬细胞 Raw 264.7 用 Cyclophosphamide hydrate (10-250 μg/mL) 处理 48 h,使用 MTT assay 检测细胞活力。 结果:Cyclophosphamide hydrate 对 Raw 264.7 有细胞毒性,IC50 为 145.44 μg/mL。[1] 方法:人乳腺癌细胞 MDA-MB-231 和 MDA-MB-435S 用 Cyclophosphamide hydrate (0.25-1 mM) 处理 4-24 h,使用 Wound healing assay 检测细胞迁移情况。 结果:迁移的 MDA-MB-231 细胞数量的增加取决于 Cyclophosphamide 的浓度,而到 MDA-MB-435S 细胞的迁移显著减少,并且与 Cyclophosphamide 浓度无关。[2] |
体内活性 |
方法:为检测体内抗肿瘤活性,将 Cyclophosphamide hydrate (50-150 mg/kg) 单次腹腔注射给携带小鼠结直肠肿瘤 CT26 的 BALB/c 小鼠。 结果:Cyclophosphamide hydrate 诱导肿瘤体积显著减少。[3] 方法:为检测体内抗肿瘤活性,将 Cyclophosphamide hydrate (140 mg/kg) 口服给药给携带小鼠乳腺癌肿瘤 4T1 的 Balb/c 小鼠,每六天一次,持续十八天。 结果:Cyclophosphamide hydrate 治疗显著抑制了小鼠的肿瘤生长。[4] |
激酶实验 | 9L cells are treated with drug for the times indicated in each experiment. Floating and attached cells are collected, pooled, resuspended in lysis buffer (10 mM HEPES buffer, pH 7.4, containing 2 mM EDTA, 0.1% CHAPS detergent, 5 mM DTT, 350 ng/mL phenylmethylsulfonyl fluoride, 10 ng/mL pepstatin A, 10 ng/mL aprotinin, and 20 ng/mL leupeptin) and lysed by three freeze-thaw cycles (alternating between a dry ice isopropanol bath and a 37°C water bath). Lysates are spun in a bench top centrifuge at full speed for 15 min and the supernatant (cell extract) fraction transferred to a new tube. Cell extracts (20 μL) are assayed for caspase 9, caspase 8, and caspase 3 activity by incubation at 37°C for either 1 h (caspase 3) or 3 h (caspase 9 and caspase 8) in 500 μL of reaction buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, and 5 mM DTT) containing 50 μM caspase form-selective substrate: Ac-LETD-AFC for caspase 8; Ac-LEHD-AFC for caspase 9; and Ac-DEVD-AMC for caspase 3. Background activity is determined for each sample as follows. Cell extracts are preincubated for 15 min at room temperature, with or without caspase form-selective inhibitor: 1 μM z-LETD-FMK for caspase 8, 1 μM z-LEHD-FMK for caspase 9, and 5 μL of Casputin for caspase 3. Caspase activity measured in the absence of inhibitor is divided by the background caspase activity measured in the presence of inhibitor. A value of 1 is subtracted from each measured activity, such that a caspase activity of 0 corresponds to no increase in the specific caspase activity with drug treatment. Fluorescence of the caspase product (excitation at 395 nm and emission at 525 nm for AFC substrates, and excitation at 380 nm and emission at 460 nm for the AMC substrate) is measured using a Shimadzu model RF-1501 spectrofluorophotometer and the manufacturer's PC-1501 software package. |
细胞实验 | 9L/pBabe, 9L/Bax, and 9L/Bcl-2 cells are treated with 12, 24, or 50 μM MFA for 72 h. Cells remaining on the plates at 0, 24, 48, and 72 h are washed twice with cold PBS and then stained for 5 min with crystal violet [1.25 g of crystal violet dissolved in a solution containing 50 mL of 37% formaldehyde and 450 mL of methanol]. The stained cells are washed three times in tap water and the plates are allowed to dry. The stain is eluted from the cells with 70% ethanol and the absorbance is then read at 595 nm. The staining intensity of each drug-treated sample (A?595) is then graphed as a percentage of the staining intensity at the 0-h time point. |
别名 | 环磷酰胺一水物, Cyclophosphamide monohydrate, 环磷酰胺水合物 |
分子量 | 279.1 |
分子式 | C7H17Cl2N2O2P·H2O |
CAS No. | 6055-19-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 51 mg/mL (182.7 mM)
H2O: 7 mg/mL (25.08 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 3.5829 mL | 17.9147 mL | 35.8295 mL | 89.5736 mL |
5 mM | 0.7166 mL | 3.5829 mL | 7.1659 mL | 17.9147 mL | |
10 mM | 0.3583 mL | 1.7915 mL | 3.5829 mL | 8.9574 mL | |
20 mM | 0.1791 mL | 0.8957 mL | 1.7915 mL | 4.4787 mL | |
DMSO | 50 mM | 0.0717 mL | 0.3583 mL | 0.7166 mL | 1.7915 mL |
100 mM | 0.0358 mL | 0.1791 mL | 0.3583 mL | 0.8957 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cyclophosphamide hydrate 6055-19-2 DNA Damage/DNA Repair Immunology/Inflammation MRP DNA Alkylator/Crosslinker DNA Cyclophosphamide Monohydrate inhibit Cyclophosphamide 环磷酰胺一水物 Cyclophosphamide Hydrate Cyclophosphamide monohydrate 环磷酰胺水合物 Inhibitor inhibitor